Associated Papers
The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers.
Zhang Y et al.
Nature Communications, 2022
35650238 (PubMed )
Supplement: 41467_2022_30708_MOESM1_ESM.pdf
Whole-Exome Sequencing Reveals Clinical Potential of Circulating Tumor DNA from Peritoneal Fluid and Plasma in Endometrial Cancer.
Ju HY et al.
Cancers, 2022
35626111 (PubMed )
Supplement: cancers-14-02506-s001.zip › Supplementary_Tables.xlsx › Supplementary_Table_S2
A stop-gain mutation in GXYLT1 promotes metastasis of colorectal cancer via the MAPK pathway.
Peng L et al.
Cell Death & Disease, 2022
35459861 (PubMed )
Supplement: 41419_2022_4844_MOESM4_ESM.xlsx › Supplementary_Table_3
ROBO1 p.E280* Loses the Inhibitory Effects on the Proliferation and Angiogenesis of Wild-Type ROBO1 in Cholangiocarcinoma by Interrupting SLIT2 Signal.
Zhou T et al.
Frontiers in Oncology, 2022
35615148 (PubMed )
Supplement: DataSheet_1.xlsx › Sheet1
eVIP2: Expression-based variant impact phenotyping to predict the function of gene variants.
Thornton AM et al.
Plos Computational Biology, 2021
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.
Schütte M et al.
Nature Communications, 2017
28186126 (PubMed )
Supplement: ncomms14262-s8.xlsx › all_discordant_SNVs_Indels
Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer.
Gnad F et al.
Bmc Genomics, 2015
26110843 (PubMed )
Supplement: 1471-2164-16-S8-S5-S7.xls › RecurrentMutations
Select a paper to view details